Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma

Respiratory Medicine

Volumn 97, Issue SUPPL. 2, 2003, Pages

  Terzano, C ^a   Ricci, A ^a   Burinschi, V ^b   Nekam, K ^c   Lahovsky, J ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Institute of Physiopulmonology   (Moldova)

^c Dept Allergol and Clin Immunol ^*  (Czech Republic)

Author keywords

Asthma; Beclometasone dipropionate; Fluticasone propionate; Nebulized drugs

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; SALBUTAMOL; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BECLOMETASONE; FLUTICASONE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPIRATORY FLOW RATE; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEBULIZATION; NEBULIZER; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; ADOLESCENT; ANALYSIS OF VARIANCE; CHRONIC DISEASE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PEAK EXPIRATORY FLOW; PHYSIOLOGY; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CHRONIC DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; VITAL CAPACITY;

EID: 11144326914     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)90076-X     Document Type: Article

References (13)

1. O'Callaghan C, Barry P. Delivering inhaled corticosteroids to patients. BMJ 1999; 8: 410-411.
2. Dahl R, Lundback B, Malo JL, Mazza JA, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
3. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. High-dose inhaled steroids in asthmatics: Moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society. Eur Respir J 1994; 7: 2179-2184.
4. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 1993; 48: 817-823.
5. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
6. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 1993; 6: 877-885.
7. Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy 1994; 49: 380-385.
8. European Respiratory Society. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Resp J 1993; 6: 1-100.
9. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: The importance of rigorous methods. BMJ 1996; 313: 36-39.
10. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875.
11. Busse WW. What role for inhaled steroids in chronic asthma? Chest 1993; 104: 1565-1571.
12. Terzano C, Barkai L, Cremonesi G. Corticosteroids administered by nebulization to children with bronchial asthma. Adv Ther 2001; 18: 253-260.
13. Terzano C, Allegra L, Barkai L, Cremonesi G. Beclomethasone dipropionate vs budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci 2001; 5: 17-24.